July 6, 2020 / 6:22 AM / a month ago

BRIEF-Inventiva To Reduce Number Of Patients In Lanifibranor Phase II Trial

July 6 (Reuters) - INVENTIVA SA:

* INVENTIVA ANNOUNCES THE DECISION BY THE INVESTIGATOR TO REDUCE THE NUMBER OF PATIENTS IN THE ONGOING PHASE II TRIAL EVALUATING LANIFIBRANOR IN TYPE 2 DIABETES PATIENTS (T2DM) WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD)

* PHASE II TRIAL RESULTS ARE EXPECTED IN 2021

* NUMBER OF PATIENTS TO BE RECRUITED IN TRIAL EVALUATING LANIFIBRANOR IN PATIENTS WITH T2DM AND NAFLD HAS BEEN REDUCED TO 34 (VERSUS 64 INITIALLY) Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below